In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Eli Lilly (NYSE:LLY) announced Thursday that its diabetes therapy, Mounjaro (tirzepatide), succeeded in a late-stage trial ...

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...

A recent study shows the use of GLP-1 drugs can increase the risk for optic nerve damage in the first year of treatment, ...

Dulaglutide injection should be given subcutaneously in the abdomen, thigh or upper arm once e every week at any time of the day. The initial dose is 0.75 mg once a week.

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist In AWARD-7, eligible patients (N=577) were randomized to receive dulaglutide 1.5mg once-weekly (N=193), dulaglutide 0 ...

The FDA approved Eli Lilly’s dulaglutide (Trulicity) for the reduction of major adverse cardiovascular events in adults with type 2 diabetes (T2D), with and without established cardiovascular ...

More Chinese adults with type 2 diabetes reduced their HbA1c to below 7% while not gaining weight or experiencing hypoglycemia when assigned dulaglutide vs. glimepiride or insulin glargine ...

British Columbia's Ministry of Health is limiting the sales of two more diabetes drugs to curb their off-label use for weight loss and preserve supply for people who are diabetic.